ICU Medical Investor Presentation — March 2022 - ICU Medical

Document content

Institutional Investors Conference

March 2022Disclosures

>Any statement concerning Management’s expectation with respect to future results is a forward looking statement based upon th e best

information currently available to Management and assumptions Management believes are reasonable, but Management does not int endthe

statement to be a representation as to future results.

>Future results are subject to risks and uncertainties, including the risk factors described in the Company’s filings with the Securities and

Exchange Commission, which include those in the most recent Form 10- K and subsequent filings. Actual results in the future may d iffer

materially from Management’s current expectations.

>These forward- looking statements, including statements about the potential impacts of the COVID -19 pandemic, are made based upon our

current expectations and we undertake no duty to update information provided in this presentation.

>This presentation contains financial measures that are not calculated in accordance with U.S. generally accepted accounting p rinciples

("GAAP"). These non -GAAP financial measures should be considered supplemental to, and not as a substitute for, or superior to, f inancial

measures calculated in accordance with GAAP. Our Management believes that the non- GAAP data provides useful supplemental inform ation

to management and investors regarding our performance and facilitates a more meaningful comparison of results of operations betw een

current and prior periods.

>Our non- GAAP financial measures include revenue presented on a constant currency basis, which uses the average exchange rate for

revenues from the prior year applied to the current year results.

2Strategic Rationale and Industrial Logic for Smiths Medical Acquisition

>Complementary product portfolios joined to create a leading IV

therapy company and simplify customer workflow

>Addition of logical adjacencies to expand available markets

>Unites two OUS operating footprints into a scaled global company

>Creates a leading US -domiciled company to add diversity and

resiliency to the medical supply chain

>Allows for multiple growth vectors through appealing products across

hospital, alt site, pharmacy, and home

>Leverages significant investment into integration and infrastructure created with Hospira Infusion Systems acquisition

3•$2.4 billion in combined pro forma revenues

•Nearly 15,000 employees worldwide

•Significant focus and scalein Infusion Therapy globally